Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is attractive because it combines durable commercial franchises with multiple growth catalysts, led by Dupixent’s proven real-world efficacy, long-term safety, and room for expansion into additional type 2 inflammatory diseases. Its eye-care platform also looks well positioned, with rapid adoption of high-dose aflibercept and an Eylea HD pre-filled syringe approval expected this qtr, while the $3.4B buyback provides support if shares weaken. The company’s fully integrated model, Phase I-III antibody pipeline, and lucrative partnerships with Sanofi and Bayer strengthen its outlook, though negotiations around the collaboration agreement could improve economics further.

Regeneron Pharmaceuticals is facing a fundamental mix of franchise erosion and pipeline uncertainty, with Eylea expected to lose share over time to biosimilars, new entrants, and IRA pressure while Dupixent’s exclusivity and growth path remain clouded by LOE litigation and competition. Near-term upside appears limited because substantial outperformance would require a multi-$B pipeline win, clearer Dupixent lifecycle protection, or major external business development, none of which seem imminent. The bearish case is reinforced by the fianlimab Phase III miss in 1L metastatic melanoma, which underscores clinical and regulatory risk across oncology and could pressure estimates further if other programs disappoint.